Rhinomed Limited has received purchase orders and begun supplying NSW Health Pathology with an initial one million Rhinoswabs as part of their program to support testing capability. The company has commenced deliveries with these initial orders being fulfilled over coming weeks. Rhinomed
is now scaling up its manufacturing facilities to respond to growing domestic and international demand for this innovative technology. Rhinomed has leveraged its deep expertise in wearable nasal medical devices to develop a novel nasal swab that is easier, and more comfortable to use. Interim results from a recent comparison study (n= 204) being completed at CWZ and Radboud University Medical Center, a leading teaching hospital in Nijmegen in the Netherlands are in line with the previously announced user study results and showed participants' strong preference for the Rhinoswab when compared to the traditional nasal swab: 89% of respondents preferred Rhinoswab to the Nasopharyngeal swab;98% of respondents felt no pain with Rhinoswab vs 48% with Nasopharyngeal swab; 98% of respondents needed little or no guidance when using RhinoswabTM.